Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05005273 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05005273 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1 participants.
The verdict
NCT05005273, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of BMS-986207 in combination with nivolumab and ipilimumab as first-line treatment for participants with stage IV non-small cell lung cancer (NSCLC).
Interventions
- OTHER Placebo
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG BMS-986207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2022-12-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05005273
The ClinicalTrials.gov registry entry for NCT05005273 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05005273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05005273 about?
NCT05005273 is a clinical study titled "A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer". The purpose of this study is to determine the safety and efficacy of BMS-986207 in combination with nivolumab and ipilimumab as first-line treatment for participants with stage IV non-small cell lung cancer (NSCLC).
What is the current status of trial NCT05005273?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2022-10-03. Estimated completion is 2022-12-27.
What interventions are being tested in trial NCT05005273?
The interventions under investigation include: Placebo (OTHER), Nivolumab (DRUG), Ipilimumab (DRUG), BMS-986207 (DRUG).
Who is sponsoring clinical trial NCT05005273?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.